These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 21962403)
1. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403 [TBL] [Abstract][Full Text] [Related]
2. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688 [TBL] [Abstract][Full Text] [Related]
3. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure. Ptaszynska-Kopczynska K; Marcinkiewicz-Siemion M; Lisowska A; Waszkiewicz E; Witkowski M; Jasiewicz M; Miklasz P; Jakim P; Galar B; Musial WJ; Kaminski KA Cytokine; 2016 Apr; 80():7-12. PubMed ID: 26916171 [TBL] [Abstract][Full Text] [Related]
4. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients. Rusu CC; Racasan S; Kacso IM; Ghervan L; Moldovan D; Potra A; Patiu IM; Bondor C; Caprioara MG Int Urol Nephrol; 2015 Dec; 47(12):2023-30. PubMed ID: 26433887 [TBL] [Abstract][Full Text] [Related]
5. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study. Díaz-López A; Chacón MR; Bulló M; Maymó-Masip E; Martínez-González MA; Estruch R; Vendrell J; Basora J; Díez-Espino J; Covas MI; Salas-Salvadó J J Clin Endocrinol Metab; 2013 Aug; 98(8):3482-90. PubMed ID: 23760626 [TBL] [Abstract][Full Text] [Related]
6. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Kowal-Bielecka O; Bielecki M; Guiducci S; Trzcinska-Butkiewicz B; Michalska-Jakubus M; Matucci-Cerinic M; Brzosko M; Krasowska D; Chyczewski L; Kowal K Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality. Mrak D; Zierfuss B; Höbaus C; Herz CT; Pesau G; Schernthaner GH Atherosclerosis; 2021 Jan; 317():41-46. PubMed ID: 33378730 [TBL] [Abstract][Full Text] [Related]
8. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension. Jasiewicz M; Kowal K; Kowal-Bielecka O; Knapp M; Skiepko R; Bodzenta-Lukaszyk A; Sobkowicz B; Musial WJ; Kaminski KA Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423 [TBL] [Abstract][Full Text] [Related]
9. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. Llauradó G; González-Clemente JM; Maymó-Masip E; Subías D; Vendrell J; Chacón MR PLoS One; 2012; 7(8):e43919. PubMed ID: 22937125 [TBL] [Abstract][Full Text] [Related]
10. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587 [TBL] [Abstract][Full Text] [Related]
11. Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease. Urbonaviciene G; Frystyk J; Flyvbjerg A; Urbonavicius S; Henneberg EW; Lindholt JS Int J Cardiol; 2012 Oct; 160(2):89-94. PubMed ID: 21463908 [TBL] [Abstract][Full Text] [Related]
12. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462 [TBL] [Abstract][Full Text] [Related]
18. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112 [TBL] [Abstract][Full Text] [Related]
19. Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. Urbonaviciene G; Frystyk J; Flyvbjerg A; Henneberg EW; Lindholt JS Atherosclerosis; 2010 Jun; 210(2):619-24. PubMed ID: 20096841 [TBL] [Abstract][Full Text] [Related]
20. Role of the tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in autoimmune thyroid disease. Peng S; Yu X; Zhao X; Wang X; Sun X; Han C; Shan Z; Li C; Teng W Clin Endocrinol (Oxf); 2017 Dec; 87(6):783-790. PubMed ID: 28636775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]